Anisomycin, SB203580 [45 (link)], SP600125, and ferrostatin-1 [46 (link)] were purchased from MCE (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO). Cells were treated with anisomycin at the indicated concentration or coincubated with SB203580 (20 μM) or ferrostatin-1 (4 μM). Commercially available antibodies were used in this study. The anti-tubulin antibody was obtained from InTech (Shanghai, China), while anti-c-Myc (#18583), CD133 (#64326), Nanog (#4903), EpCAM (#2929), caspase-3 (#14220), Bcl-2 (#15071), Bax (#5023), N-cadherin (#13116), E-cadherin (#3195), vimentin (#5741), α-smooth muscle actin (α-SMA, #19245), p38 MAPK (#8690), phospho-p38 MAPK (p-p38 MAPK, #9216), histone H3 (#4499), phospho-histone H3 (Ser10) (p-H3S10, #53348), phospho-histone H3 (Ser28) (p-H3S28, #9713), NRF2 (#12721), SLC7A11 (#12691), FTH1 (#4393), and NCOA4 (#66849) antibodies were purchased from Cell Signaling Technology (Boston, USA). Anti-CD24 (ab31622) antibody was provided by Abcam (Cambridge, UK).
Free full text: Click here